Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class ITerminatedD-0765-2022

Drug recall · April 20, 2022

IDArubicin Hydrochloride Injection USP 5gm/5mL recall

Why: Presence of Particulate Matter: Product was found to contain silica and iron oxide

Class I: a reasonable chance the product could cause serious harm or death.

The recall

Product

IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11.

Lots / codes

Lot #: 31329657B, Exp. Date 08/2023

Quantity
1565 vials
Company
Teva Pharmaceuticals USA Inc, Parsippany, NJ
Distribution
Nationwide within the United States
Initiated
March 29, 2022 · Voluntary: Firm initiated
Classified
April 11, 2022
Reported
April 20, 2022
Ended
June 20, 2023
How notified
Letter

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.